Now, ST101, a peptide antagonist targeting C/EBPβ, is in phase 1/2 clinical trials for advanced solid tumors, including glioblastoma, breast cancer, melanoma, and other refractory malignancies. Here, CEBPB is linked to breast carcinoma.